Fosfomycin

Fosfomycin

SCHEMBL3168937

C[C@H]1O[C@H]1P(=O)(O)O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

murA

The experimentally established mechanism targets of Fosfomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fosfomycin SCHEMBL3168929 1.00
Fosfomycin SCHEMBL8633252 1.00
Fosfomycin SCHEMBL9634477 1.00
Fosfomycin SCHEMBL10492648 1.00
Fosfomycin SCHEMBL989825 1.00
Fosfomycin SCHEMBL50951 1.00
Fosfomycin SCHEMBL5595663 1.00 LMNA (0.50)
Fosfomycin SCHEMBL989824 0.97
Fosfomycin SCHEMBL9634052 0.97 LMNA (0.48)
Fosfomycin SCHEMBL20597804 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5191094-A Mono (2-ammonium-2-hydroxymethyl-1,3-propanediol) (2R,cis)-1,2-epoxypropyl-phosphonate with improved characteristics of stability and processing ZAMBON GROUP S.P.A. (IT) 1993-03-02 US claimed
US-5162309-A Urogenital disorders ZAMBON GROUP (IT) 1992-11-10 US claimed
EP-0299484-A1 Process for the preparation of intermediates for the synthesis of fosfomycin ZAMBON GROUP S.p.A. (IT) 1989-01-18 EP claimed
JP-58134028-A None JP disclosed
EP-4678176-A1 AMINO ACID SALTS OF FOSFOMYCIN AND COMPOSITIONS THEREOF Ercros, S.A. (ES) 2026-01-14 EP disclosed
EP-3220920-B1 COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS FLEURIR ABX LLC (US) 2025-06-04 EP disclosed
US-20240293434-A1 COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS FLEURIR ABX LLC (US) 2024-09-05 US disclosed
US-11925653-B2 Combination therapy effective against microorganisms, including drug resistant microorganisms FLEURIR ABX, LLC (US) 2024-03-12 US disclosed
US-11833250-B2 Fosfomycin tablet formulations LABIANA HEALTH, S.L. (ES) 2023-12-05 US disclosed
US-20220233557-A1 Combination Therapy Effective Against Microorganisms, Including Drug Resistant Microorganisms FLEURIR ABX LLC (US) 2022-07-28 US disclosed
US-10980811-B2 Reversal of fosfomycin resistance University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2021-04-20 US disclosed
US-4479898-A Oligopeptide prodrugs SMITHKLINE BECKMAN CORPORATION (US) 1984-10-30 US disclosed
US-4454065-A INCREASE CELL MEMBRANE PERMEABILITY SMITHKLINE BECKMAN CORPORATION (US) 1984-06-12 US disclosed
JP-S58134028-A AGENT FOR MITIGATING OR PREVENTING RENAL TOXICITY OF AMINOGLUCOSIDE ANTIBIOTIC SUBSTANCE MEIJI SEIKA KAISHA LTD 1983-08-10 JP disclosed
US-3943153-A BACTERICIDES MERCK & CO., INC. (US) 1976-03-09 US disclosed
US-3943153-A BACTERICIDES MERCK & CO., INC. (US) 1976-03-09 US disclosed
US-3935309-A CHLORAMPHENICOL MERCK & CO., INC. (US) 1976-01-27 US disclosed
US-3929840-A Labile esters of ({31 )(cis-1,2-epoxypropyl)phosphonic MERCK & CO INC 1975-12-30 US disclosed
US-3914231-A ({31 )(Cis-1,2-epoxypropyl)-phosphonic acid and salts thereof MERCK & CO INC 1975-10-21 US disclosed
US-3862148-A P-(-)-(CIS-1,2-EPOXYPROPYL)-ISOHYPOPHOSPHORIC ACID COMPOUNDS MERCK & CO INC 1975-01-21 US disclosed